4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamide | 66063-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamide
• 英文别名: 4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzamide
• CAS: 66063-38-5
• 化学式: C₁₅H₁₆N₈O
• 分子量: 324.34
• InChiKey: QZOTWJDGJRTBLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] PRODRUGS ACTIVATED BY REACTIVE OXYGEN SPECIES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES AND CANCER<br/>[FR] PROMÉDICAMENTS ACTIVÉS PAR DES ESPÈCES RÉACTIVES DE L'OXYGÈNE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET DU CANCER
  申请人：UNIV DANMARKS TEKNISKE

  公开号：WO2018037120A1

  公开（公告）日：2018-03-01

  Prodrugs activated predominantly or exclusively in inflammatory tissue, more particularly prodrugs of methotrexate and derivatives thereof, which are selectively activated by Reactive Oxygen Species (ROS) in inflammatory tissues associated with cancer and inflammatory diseases, as well as method for preparing said prodrugs.

  主要或专门在炎症组织中激活的前药，尤其是甲氨蝶呤及其衍生物的前药，这些前药通过活性氧种（ROS）在与癌症和炎症性疾病相关的炎症组织中选择性激活，以及用于制备所述前药的方法。
• [EN] METHOTREXATE ANALOGS AND METHODS OF USE<br/>[FR] ANALOGUES DE MÉTHOTREXATE ET PROCÉDÉS D'UTILISATION
  申请人：US HEALTH

  公开号：WO2021262693A1

  公开（公告）日：2021-12-30

  Compounds having general formula (I) or a pharmaceutically acceptable salt, N-oxide, or hydrate thereof are provided herein. Also provided are methods of making the compounds and methods of their use, including in treatment of cancer, autoimmune disorders, and viral infections.

  本文提供了具有通式（I）或其药用可接受的盐、N-氧化物或水合物的化合物。还提供了制备这些化合物的方法以及它们的使用方法，包括在癌症、自身免疫性疾病和病毒感染的治疗中的应用。
• Methods for treating and diagnosing blinding eye diseases
  申请人：Translatum Medicus Inc.

  公开号：US10265418B2

  公开（公告）日：2019-04-23

  This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).

  本发明部分涉及有助于诊断、治疗或预防致盲性眼病的方法和组合物，包括发现对这些疾病有效的药物。疾病包括，例如，与年龄相关的黄斑变性和网状假性变性疾病，本文所述的方法包括，例如，名为延迟近红外分析（DNIRA）的方法。
• Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
  申请人：Melin Jeffrey M.

  公开号：US10952994B2

  公开（公告）日：2021-03-23

  A formulation, especially one that is topically administered, comprising a combination of rapamcycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat a condition or disease of the skin or eye, wherein the condition or disease is associated with mTORC1 activation.

  一种制剂，尤其是局部给药的制剂，包含雷帕霉素和二甲双胍的组合，摩尔比约为 20:1、10:1、5:1、4:1、3:1 或 1:1。外用制剂可以是凝胶、软膏、霜剂或乳液。外用制剂可用于治疗皮肤或眼部的病症或疾病，其中病症或疾病与 mTORC1 激活有关。
• COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS
  申请人：BOYD Shelley Romayne

  公开号：US20170079955A1

  公开（公告）日：2017-03-23

  Disclosed herein are methods, compounds, such as bindaret, and compositions that are useful for the diagnosis, treatment, or prevention of an ocular disorder, including the discovery of agents that are efficacious against these disorders. Also included is the use of a fluorescent compound in an amount effective to indicate the presence of said ocular disorder in order to determine the efficacity of said compounds used in the diagnosis, treatment or prevention of said ocular disorders.